Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
Therapeutic Candidates from Plants and the Pharmacology of Their Effects...
share announcement

Therapeutic Candidates from Plants and the Pharmacology of Their Effects on Atopic Dermatitis

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Natural Products".

Deadline for manuscript submissions: closed (15 February 2023) | Viewed by 9297

Special Issue Editor

Prof. Dr. Sei-Ryang Oh

E-Mail Website
Guest Editor
Branch Director (Ochang campus) of KRIBB (Korea Research Institute of Bioscience and Biotechnology, Yusong, Korea
Interests: natural products; medicinal plant; chronic inflammation

Special Issue Information

Dear Colleagues,

Atopic dermatitis (AD), a representative disease of eczema, causes severe itching and deterioration of the skin barrier caused by a combination of external stimuli (allergens) and chronic inflammation that trigger symptoms, and AD is generally induced or its progress facilitated by T cell-mediated chronic inflammation, involving various immune cells and mediators.

Although steroids (local, systemic) and immunomodulatory agents are used clinically, synthetic drugs are known to have significant side effects following long-term use. Natural products from plant sources, which are generally safer than synthetics, have been investigated in developing therapeutic candidates for AD treatment that suppress the activation inflammatory events in the skin.

This Special Issue has the purpose of introducing the latest research on natural compounds and extracts as potential drug candidates in addition to suggesting future directions for the development of AD therapeutics.

Prof. Dr. Sei-Ryang Oh
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atopic dermatitis
  • skin barrier
  • inflammation
  • cytokine
  • anti-inflammation
  • phytochemical
  • natural product
  • plant source
  • therapeutic candidate

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 5886 KiB  
Article
Anti-Atopic Dermatitis Effects of Abietic Acid Isolated from Rosin under Condition Optimized by Response Surface Methodology in DNCB-Spread BALB/c Mice
by Jumin Park, Ji Eun Kim, You Jeong Jin, Yu Jeong Roh, Hee Jin Song, Ayun Seol, So Hae Park, Sungbaek Seo, Heeseob Lee and Dae Youn Hwang
Pharmaceuticals 2023, 16(3), 407; https://doi.org/10.3390/ph16030407 - 07 Mar 2023
Cited by 3 | Viewed by 2026
Abstract
Abietic acid (AA) is known to have beneficial effects on inflammation, photoaging, osteoporosis, cancer, and obesity; however, its efficacy on atopic dermatitis (AD) has not been reported. We investigated the anti-AD effects of AA, which was newly isolated from rosin, in an AD [...] Read more.
Abietic acid (AA) is known to have beneficial effects on inflammation, photoaging, osteoporosis, cancer, and obesity; however, its efficacy on atopic dermatitis (AD) has not been reported. We investigated the anti-AD effects of AA, which was newly isolated from rosin, in an AD model. To achieve this, AA was isolated from rosin under conditions optimized by response surface methodology (RSM), and its effects on cell death, iNOS-induced COX-2 mediated pathway, inflammatory cytokine transcription, and the histopathological skin structure were analyzed in 2,4-dinitrochlorobenzene (DNCB)-treated BALB/c mice after treatment with AA for 4 weeks. AA was isolated and purified through isomerization and reaction-crystallization under the condition (HCl, 2.49 mL; reflux extraction time, 61.7 min; ethanolamine, 7.35 mL) established by RSM, resulting in AA with a purity and extraction yield of 99.33% and 58.61%, respectively. AA exhibited high scavenging activity against DPPH, ABTS, and NO radicals as well as hyaluronidase activity in a dose-dependent manner. The anti-inflammatory effects of AA were verified in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through amelioration of the inflammatory response, including NO production, iNOS-induced COX-2 mediated pathway activation, and cytokine transcription. In the DNCB-treated AD model, the skin phenotypes, dermatitis score, immune organ weight, and IgE concentration were significantly ameliorated in the AA cream (AAC)-spread groups compared to the vehicle-spread group. In addition, AAC spread ameliorated DNCB-induced deterioration of skin histopathological structure through the recovery of the thickness of the dermis and epidermis and the number of mast cells. Furthermore, activation of the iNOS-induced COX-2 mediated pathway and increased inflammatory cytokine transcription were ameliorated in the skin of the DNCB+AAC-treated group. Taken together, these results indicate that AA, newly isolated from rosin, exhibits anti-AD effects in DNCB-treated AD models, and has the potential to be developed as a treatment option for AD-related diseases. Full article
(This article belongs to the Special Issue Therapeutic Candidates from Plants and the Pharmacology of Their Effects on Atopic Dermatitis)
►▼ Show Figures

Figure 1

14 pages, 2988 KiB  
Article
Callicarpa dichotoma Leaf Extract Alleviates Atopic Dermatitis through the Suppression of T Cells and Keratinocytes Activation
by Eun-Nam Kim, Hyun-Su Lee and Gil-Saeng Jeong
Pharmaceuticals 2022, 15(10), 1280; https://doi.org/10.3390/ph15101280 - 18 Oct 2022
Cited by 2 | Viewed by 1858
Abstract
Atopic dermatitis (AD) is a highly recurrent chronic inflammatory skin disease, characterized by severe itching, immune imbalance, and skin barrier dysfunction. Damage to the skin barrier function is known to be the main cause of Th1/Th2 immune imbalance, due to the Th2-mediated immune [...] Read more.
Atopic dermatitis (AD) is a highly recurrent chronic inflammatory skin disease, characterized by severe itching, immune imbalance, and skin barrier dysfunction. Damage to the skin barrier function is known to be the main cause of Th1/Th2 immune imbalance, due to the Th2-mediated immune response, and pro-inflammatory cytokines, including IL-4, IL-5, IL-13 and IL-31 and it plays an important role in further eliciting the environment of AD through stimulation. Currently, the most widely used drugs for the treatment of AD are corticosteroids, antihistamines and immunosuppressants (used by more than 60% of patients), which are reported to exhibit various side effects when taken for a long time. Therefore, interest in the physiological activity of safer plant-derived natural extracts is increasing. Callicarpa dichotoma is traditionally used in oriental medicine for bruises, habitual pain, gastric and postpartum hemorrhage. Recent studies have reported that it exhibits antioxidant anti-inflammatory and anti-hepatotoxic activity, but the role and activity of C. dichotoma in AD have not yet been studied. Therefore, in this study, the new physiological activity of C. dichotoma in the AD environment was investigated, suggesting its potential as a natural therapeutic agent. Full article
(This article belongs to the Special Issue Therapeutic Candidates from Plants and the Pharmacology of Their Effects on Atopic Dermatitis)
►▼ Show Figures

Figure 1

18 pages, 3192 KiB  
Article
Moringa concanensis L. Alleviates DNCB-Induced Atopic Dermatitis-like Symptoms by Inhibiting NLRP3 Inflammasome-Mediated IL-1β in BALB/c Mice
by Kyeong-Min Kim, So-Yeon Kim, Tamanna Jahan Mony, Ho Jung Bae, Seung-Hyuk Choi, Yu-Yeong Choi, Ju-Yeon An, Hyun-Jeong Kim, Ye Eun Cho, Kandhasamy Sowndhararajan and Se Jin Park
Pharmaceuticals 2022, 15(10), 1217; https://doi.org/10.3390/ph15101217 - 30 Sep 2022
Cited by 8 | Viewed by 3004
Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, dry skin and redness on the face and inside elbows or knees. Most patients with AD are children and youths, but it can also develop in adults. In the therapeutic aspect, [...] Read more.
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, dry skin and redness on the face and inside elbows or knees. Most patients with AD are children and youths, but it can also develop in adults. In the therapeutic aspect, treatment with corticosteroids for AD has several side effects, such as weight loss, atrophy and acne. In the current study, we examined the anti-inflammatory effect of Moringa concanensis leaves on HaCaT keratinocytes and 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis-like symptoms in BALB/c mice. We observed that M. concanensis treatment exhibited significant inhibition in the production of inflammatory mediators and proinflammatory cytokines, such as IL-1β, in LPS-induced HaCaT keratinocytes by downregulating the NLRP3 inflammasome activation. Moreover, M. concanensis inhibited the activation of JNK, AP-1 and p65, which resulted in the deformation of NLRP3 in LPS-stimulated HaCaT cells. In mice with DNCB-induced AD-like skin lesions, the administration of M. concanensis ameliorated the clinical symptoms, such as the dermatitis score, thickness of lesional ear skin and TEWL. Furthermore, M. concanensis could attenuate the activation of the immune system, such as reducing the spleen index, concentration of the IgE levels and expression of the NLRP3 inflammasome in ear tissues. Therefore, our results suggest that M. concanensis exerts anti-atopic dermatitis effects by inhibiting the NLRP3 inflammasome-mediated IL-1β. Full article
(This article belongs to the Special Issue Therapeutic Candidates from Plants and the Pharmacology of Their Effects on Atopic Dermatitis)
►▼ Show Figures

Graphical abstract

11 pages, 1982 KiB  
Article
Therapeutic Potentials of Secoiridoids from the Fruits of Ligustrum lucidum Aiton against Inflammation-Related Skin Diseases
by Sang Won Yeon, Su Ryeon Choi, Qing Liu, Yang Hee Jo, Da Hee Choi, Mi Ran Kim, Se Hwan Ryu, Solip Lee, Bang Yeon Hwang, Hyung Seo Hwang and Mi Kyeong Lee
Pharmaceuticals 2022, 15(8), 932; https://doi.org/10.3390/ph15080932 - 27 Jul 2022
Cited by 3 | Viewed by 1920
Abstract
Ligustrum lucidum Aiton is a flowering plant of the Oleaceae family, and its fruits have been traditionally used for skin nourishment and the treatment of skin diseases. However, the anti-inflammatory constituents for skin disease are not well-characterized. Phytochemical investigation of L. lucidum fruits [...] Read more.
Ligustrum lucidum Aiton is a flowering plant of the Oleaceae family, and its fruits have been traditionally used for skin nourishment and the treatment of skin diseases. However, the anti-inflammatory constituents for skin disease are not well-characterized. Phytochemical investigation of L. lucidum fruits resulted in the isolation of a new secoiridoid, secoligulene (1), together with (E)-3-(1-oxobut-2-en-2-yl)pentanedioic acid (2) and trans-(E)-3-(1-oxobut-2-en-2-yl)glutaric acid (3). Secoligulene (1) displayed the potent inhibitory effect on NO production with an IC50 value of 12.0 μg/mL. Secoligulene (1) also downregulated mRNA transcriptional levels of pro-inflammatory cytokines such as IL-1 α, IL-1β, IL-6 and COX-2 in LPS-stimulated RAW264.7 cells. Further investigation showed that secoligulene (1) inhibited the phosphorylation of IκB and JNK activated by LPS. In addition, secoligulene (1) downregulated the expression of chemokines such as CXCL8 and CCL20 in the TNF-α/IL-17/IFN-γ induced HaCaT psoriasis model. Taken together, these findings support the beneficial effects of L. lucidum and its constituents on inflammation-related skin diseases and can be further developed as therapeutic treatments for related diseases. Full article
(This article belongs to the Special Issue Therapeutic Candidates from Plants and the Pharmacology of Their Effects on Atopic Dermatitis)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop